فهرست نشریات علمی دسترسی آزاد ایران

 Background and Objectives: Adjuvant therapy is very important to reduce mortality in patients with resected pancreatic cancer. The aim of this study was to compare adjuvant modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) combination chemotherapy with gemcitabine plus capecitabine (GEMCAP) chemotherapy, by using real life data.   Methods: This is a retrospective study. A total of 87 patients with pathologically diagnosed pancreatic adenocarcinoma between January 2021 and December 2023 were included in the study. Modified FOLFIRINOX regimen was compared with GEMCAP regimen. Kaplan-meier analysis was used for Disease-Free Survival (DFS) and Overall Survival (OS).   Results: Of the total 87 patients, 52 were treated with mFOLFIRINOX, and 35 received the GEMCAP. The median DFS of patients receiving FOLFIRINOX was 20 months (95% Cl, 17.27-22.72), while the median DFS of patients receiving GEMCAP was 15 months (95% Cl, 12.32-17.64). mFOLFIRINOX treatment was significantly different from GEMCAP treatment (P<0.001).  The median OS of patients receiving mFOLFIRINOX was 43 months (95% Cl, 39.46-46.53), while those receiving GEMCAP had a median OS of 31 months (95% Cl, 28.79-33.20). The median OS of patients receiving mFOLFIRINOX was significantly better than that of patients receiving GEMCAP (P≤0.001).   Conclusion: In resected pancreatic cancer patients, mFOLFIRINOX provided a statistically significant disease-free survival and overall survival benefit compared to GEMCAP treatment. Due to its higher toxicity rates, mFOLFIRINOX is recommended as a treatment option for patients who are younger and have good performance status.